Pharmacokinetics & Dosing
Itraconazole dosing, repurposed-use ranges, and practical pharmacokinetic considerations in oncology
Itraconazole dosing in oncology is distinct from routine antifungal use because repurposing studies often use higher or protocol-specific schedules.
Dosing patterns seen in studies
continuous daily dosing: often 200–600 mg daily
cycled dosing: 400 mg daily for 4 days, repeated every 2 weeks in some retrospective combination settings
Why dosing matters
The repurposing question is not just whether itraconazole can be used. It is whether it can be used at doses that meaningfully affect tumour biology while remaining tolerable.
Practical interpretation
Published studies suggest both continuous and cyclical strategies have been explored. The right approach depends on cancer type, co-treatments, and the clinician's rationale for use.
Key References
A phase II trial in metastatic castration-resistant prostate cancer using itraconazole
https://pmc.ncbi.nlm.nih.gov/articles/PMC5536437/
Repurposing itraconazole for the treatment of cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.